about
A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System TargetsDissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein InterfaceRoute to three-dimensional fragments using diversity-oriented synthesis.Application of a sparse matrix design strategy to the synthesis of dos libraries.An inexpensive high-throughput nuclear magnetic resonance tube cleaning apparatus.The benefits of constructing leads from fragment hits.From laptop to benchtop to bedside: structure-based drug design on protein targets.Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries.Mining collections of compounds with Screening Assistant 2Translational synthetic chemistry.Stochastic voyages into uncharted chemical space produce a representative library of all possible drug-like compounds.Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)The importance of molecular complexity in the design of screening libraries.Medicinal chemistry for 2020Partially Saturated Bicyclic Heteroaromatics as an sp(3) -Enriched Fragment Collection.Divergent Synthesis and Real-Time Biological Annotation of Optically Active Tetrahydrocyclopenta[c]pyranone Derivatives.An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.The influence of the 'organizational factor' on compound quality in drug discovery.Oncogenic protein interfaces: small molecules, big challenges.An eco-compatible strategy for the diversity-oriented synthesis of macrocycles exploiting carbohydrate-derived building blocksCascade Syntheses Routes to the CentrocountinsDiels-Alder and Formal Diels-Alder Cycloaddition Reactions of Ynamines and YnamidesRecent Applications of Diversity-Oriented Synthesis Toward Novel, 3-Dimensional Fragment Collections
P2860
Q26781471-DD5C8911-6690-4D91-A5EC-495A37384D79Q27674729-9E5A2BC8-4C4D-48FF-92F1-8A026623112EQ33868796-D2772E1B-F6AA-4BDD-8482-65B801AB9F86Q33883940-CE15EE69-9E2F-44DA-AC42-187841C1F725Q33922518-470CAF2A-D6D4-4C79-8AFA-5D1ACCEDE8BDQ33977454-C42B2B59-DB21-45DF-B676-1C30C80A01D8Q34153589-6C9B50C8-2EF7-4697-B100-BD426077BABEQ34361517-4D00A962-8E66-4073-B2CA-88E48A744C23Q34552776-C58BD024-9BF9-4ED8-9125-29B208107245Q34626958-4BCC6156-1B65-4435-A503-607BB8A682EBQ34645543-D613CC71-27BB-4951-9DF3-EAFC6C36D582Q34881218-4DB73C6C-1104-46D7-950B-65EBE0ED0655Q35016524-B1343313-AFA7-40AE-8144-483970B66D47Q35593223-E29A25EF-9A14-4213-9952-4144786C3E83Q36123327-C9949D37-16B9-4C35-89F0-7A33B8A34427Q36225570-3FC27EE7-0BCB-4584-994E-E6F49BAE5C66Q36593553-E7E52990-7D26-40D7-95DC-A563868785CCQ37940789-003640FE-FDBE-46E9-BCF6-EE47C621E39CQ38195457-CA29E0FE-24BB-4869-955E-1B31B6C29BE4Q41070221-375A3FFF-7CAE-4361-8B90-BFCDF65A1135Q57006697-F7608BD6-FBCD-4207-A3F1-7DE0134E6DFEQ57776716-04B762FE-DBEE-4FC8-A8A2-A5A12BF5EAF3Q58553557-0CDF898A-B808-4909-8E74-9C20ADC708BF
P2860
description
article publié dans la revue scientifique Nature
@fr
scientific article published in Nature
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в Nature в лютому 2011
@uk
name
Drug discovery: A question of library design
@en
Drug discovery: A question of library design
@nl
type
label
Drug discovery: A question of library design
@en
Drug discovery: A question of library design
@nl
prefLabel
Drug discovery: A question of library design
@en
Drug discovery: A question of library design
@nl
P2860
P356
P1433
P1476
Drug discovery: A question of library design
@en
P2093
Philip J Hajduk
Warren R J D Galloway
P2860
P2888
P356
10.1038/470042A
P407
P577
2011-02-01T00:00:00Z
P6179
1004195074